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emodialysis Hyperhemolysis
Novel Mechanism of Endothelial
ysfunction and Cardiovascular Risk?*
henell L. Donadee, MD, Mark T. Gladwin, MD
ittsburgh, Pennsylvania
n this issue of the Journal, Meyer et al. (1) investigated the
ole of hemodialysis-induced intravascular hemolysis on
itric oxide (NO) bioavailability and vascular dysfunction in
atients with end-stage renal disease (ESRD). They showed
n increase in hemolysis and the levels of cell-free plasma
emoglobin (Hb) during hemodialysis that was associated
ith NO scavenging and impaired flow-mediated dilation,
n index of endothelial NO generation during shear stress.
his study is important because it is the first study of this
henomenon in an iatrogenic setting and it adds to a
rowing body of literature suggesting that even trace levels
f cell-free plasma Hb impair endothelial NO signaling.
his process has been termed hemolysis-associated endo-
helial dysfunction.
See page 454
Nitric oxide is a potent endogenous vasodilator produced
onically by the endothelium. It is now well accepted that
ell-free oxyhemoglobin in the plasma functions as an NO
cavenger, producing methemoglobin and nitrate (NO3
)
n a reaction that is fast and irreversible.
NO oxyHb→metHbNO3
 [Equation 1]
Normally, in the absence of hemolysis, the amount of
O scavenged by Hb is greatly limited by the Hb seques-
ration within the red blood cell plasma membrane. This
equestration produces major bulk diffusional barriers to
O, which include an unstirred layer around the red blood
ell, an intrinsic membrane permeability barrier to NO, and
cell-free zone along the endothelium in laminar flowing
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Pulmonary, Allergy, and Critical Care Medicine, University of Pitts-
urgh Medical Center, Pittsburgh, Pennsylvania; and the Vascular Medicine Insti-
ute, University of Pittsburgh, Pittsburgh, Pennsylvania. Dr. Gladwin has received
esearch grant support in the form of a Collaborative Research and DevelopmentT
greement between the U.S. government and IKARIA, and is listed as a coinventor
n a U.S. government patent for the use of nitrate salts for cardiovascular indications.lood (2,3). These combined barriers reduce the reaction
ate of NO with intracellular Hb by approximately 1,000-
old. Thus, when states of hemolysis disrupt the red blood
ell plasma membrane and release Hb into the plasma, NO
cavenging reaction rates increase by 1,000. This effect is
ompounded by the extravasation of the Hb tetramer and
imer into the interstitial space. Remarkably, kinetic models
uggest that levels of plasma Hb as low as 1 M have the
otential to impair endothelial NO signaling, and heme
oncentrations as low as 6 M have been found to impair
O-dependant vasodilation in vivo in patients with sickle
ell disease (2,4). In the current study, Meyer et al. (1) found
6.8 M heme in patients undergoing hemodialysis, nearly
times that amount. Hemolysis also releases arginase-1, an
ntracellular enzyme that when released into the plasma
eacts with L-arginine to form ornithine, effectively reduc-
ng L-arginine availability for conversion to NO by endo-
helial NO synthase (3,5–7).
The effects of cell-free plasma Hb on NO consumption
ave also been shown in clinical trials of Hb-based blood
ubstitutes, in which various cell-free Hb preparations given
o humans and animals showed dose-dependent effects on
asoconstriction, pulmonary hypertension, and systemic hy-
ertension (3,8,9). Induced intravascular hemolysis in a dog
odel produced NO consumption and subsequent vasocon-
triction and renal dysfunction (10). This phenomenon has
lso been noted in patients with sickle cell disease, a chronic
emolytic state (2). In these studies, the vasoconstrictive
ffects of NO depletion caused by hemolysis could be
ounteracted by inhaled NO, which reacts directly with the
ell-free Hb in the pulmonary circulation, oxidizing it to
ethemoglobin, which cannot then scavenge the NO sys-
emically (2,10). A recent study published in the Journal of
linical Investigation by Boretti et al. (11) reports that
ell-free plasma Hb has potent oxidative properties that are
ssociated with hypertensive effects. They also found that
ncreasing the levels of haptoglobin in the circulation
educed this oxidative stress and limited both the hyperten-
ive effects and the renal insufficiency associated with plasma
emoglobinemia.
The current proof-of-concept study byMeyer et al. (1) is the
rst to demonstrate NO consumption by cell-free Hb in the
atrogenic setting of hemodialysis. They hypothesized that
emodialysis produces an increase in cell-free Hb that would
hen scavenge NO, causing measurable vascular effects. They
easured flow-mediated dilation of the brachial artery before
nd after hemodialysis sessions in 14 patients with ESRD of
aried etiology. Flow-mediated dilation is a method that
easures the vasodilation response of the brachial artery to the
hear stress of blood flow. In this method, a blood pressure cuff
roduces hand ischemia for 5 min, and after release of the cuff
here is an acute increase in hyperemic blood flow to the arm.
his increased blood flow produces upstream increased blood
ow in the large conduit arteries (brachial and radial arteries).
his produces secondary shear stress, which activates the
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February 2, 2010:460–2 Hemodialysis Hyperhemolysisndothelial NO synthase in the endothelium, causing a sub-
equent delayed vasodilation after 30 to 60 s. This vasodilation
an be measured by assessing the brachial or radial artery
iameter using high-fidelity Doppler ultrasound. The shear-
ependent vasodilation is largely determined by endothelial
O synthase activity. Meyer et al. (1) found that flow-
ediated dilation was decreased after hemodialysis and in-
ersely correlated to the amount of cell-free Hb (p  0.041).
This finding was supported by assays that directly showed
ncreased NO consumption by the plasma collected after
emodialysis. The NO consumption by cell-free Hb was
urther substantiated by adding ferricyanide (FeCN6) to the
ost-hemodialysis plasma. The FeCN6 oxidizes heme from
he ferrous Fe2 to ferric Fe3 state, which has very low
ffinity for NO. When FeCN6 was added to the post-
emodialysis plasma, it significantly decreased the affinity of
ell-free Hb for NO, and NO consumption returned to
re-hemodialysis levels. Increased levels of cell-free Hb and
rginase-1 were found in the post-hemodialysis samples,
resumably caused by hemolysis from the hemodialysis
reatment and mechanical hemolysis of red blood cells.
owever, other markers of hemolysis, such as increased
actate dehydrogenase, bilirubin, haptoglobin, and change in
mount of red blood cells, were not detected as would be
xpected with red blood cell breakdown (1). This is surprising,
ut may be caused by very small changes in their levels that
ere not detectable by the quantifying methodologies used.
Hemodialysis is a routine procedure for a large and
rowing population of patients with ESRD, a disorder
ssociated with an increased prevalence of cardiovascular
iseases such as hypertension, coronary artery disease, and
erebrovascular disease (12). This study provides evidence
or a novel mechanism of iatrogenically induced vascular
ysfunction in this at-risk population. The vascular changes
etected also raise concern about other clinical procedures
hat may produce similar hemolysis because of mechanical
hearing forces such as extracorporeal membrane oxygen-
tion, cardiopulmonary bypass, ventricular assist devices,
nd intraoperative blood salvage machines. We hypothesize
hat this phenomenon may be operative in red blood cell
ransfusion, especially in cases of older blood or massive
ransfusions in which there is a reduced red cell life span
fter infusion. Further investigation into cell-free plasma
b-mediated NO consumption in these clinical settings is
learly warranted.
Appreciation of a role for iatrogenic hemolysis and
emolysis-associated endothelial dysfunction leads to po-
ential novel approaches to therapy. Initial studies indicate
hat this may be in the form of NO donors or exogenous
aptoglobin, which could possibly be administered with
D or other inciting procedures to counteract these vascu-
ar effects (2,10,11). Another development in our under-
tanding of Hb–NO biology is the appreciation that Hb
ossesses a nitrite reductase and anhydrase activity that can
onvert nitrite to NO and N2O3, respectively, offsetting the
b-dependent NO scavenging by vasodilation. Nitrite re-cts with deoxygenated Hb to form methemoglobin and
O (13–15).
NO2
HbFe2H→NOHbFe3OH
[Equation 2]
We have shown that this reaction is under allosteric
ontrol, so that it is most efficient near the Hb P50 (where
he hemes are half-saturated with oxygen) and contributes
o the control of blood flow (13,16–18). Recently, we have
iscovered that export of NO activity may involve the
ntermediacy of N2O3 through anhydrase activity (19),
here this reaction occurs via a fast reaction of NO and
bFe3 bound to nitrite.
2NO2
HbFe2H→HbFe2N2O3OH

[Equation 3]
Consistent with this theory, 2 recent studies have exam-
ned the addition of nitrite to Hb-based oxygen carriers and
ound that low concentrations of nitrite reverse the vaso-
onstrictive effects (20,21). According to this hypothesis,
ow doses of nitrite could be given before hemodialysis,
ardiopulmonary bypass, or transfusion of aged blood to
imit the cardiovascular toxicity of NO scavenging.
In summary, confirmation of the current studies would
uggest that hemodialysis-associated endothelial dysfunc-
ion caused by NO scavenging by cell-free plasma Hb may
ffect a very large population and open the door to novel
herapies that could limit this pathobiology.
eprint requests and correspondence: Dr. Mark T. Gladwin,
ulmonary, Allergy, and Critical Care Medicine, NW 628 Mon-
efiore Hospital, 3459 Fifth Avenue, Pittsburgh, Pennsylvania
5213. E-mail: gladwinmt@upmc.edu.
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